Ottimo Pharma is an innovative, clinical-stage, biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of patients living with cancer
Ottimo Pharma is an innovative, clinical-stage, biotech company developing one-of-a-kind PD-1/VEGFR2 dual-paratopic antibodies to extend the lives of patients living with cancer.
The top three firms on F4's Biotech & Life Sciences investor list.